Method for homeostatic disorder correction in children with hepatic hemangiomas
SUBSTANCE: invention relates to medicine, particularly to paediatrics, X-ray surgery, paediatric surgery, and concerns the hemostatic disorder correction in the children with hepatic hemangiomas. For this purpose, three days before the endovascular embolisation of the hepatic hemangioma, Protromplex 600 - a preparation of plasma factors II, VII, IX, X is administered intravenously in a dose of 20 IU/kg at max. 2 ml/min; on the first postoperative day, Protromplex is administered in the same dose, and further Fraxiparine is administered subcutaneously in a dose of 158 IU/kg of body weight for 3 days.
EFFECT: presented dose schedule of the preparations provides the effective and safe correction of hemostatic disorders in the children with hepatic hemangiomas due to normalising the internal and external mechanisms of blood coagulation and fibrinolysis.
The invention relates to medicine, specifically to x-ray surgery, pediatric surgery, and can be used for the correction of disorders of hemostasis in endovascular operations for hemangiomas of the liver in children.
Liver disease lead to complex disorders of the hemostatic system while maintaining the fragile balance between coagulation and anticoagulation systems blood (Minov A.F., Zajko A.M., Rummo OO Violation of hemostasis in liver diseases. Journal of Transplantology and artificial organs. Volume XII, No. 2, 2010. S). Disorders of hemostasis, developing for hemangiomas of the liver, affect all its parts, including the system of fibrinolysis. There are four groups of disorders of hemostasis in liver pathology: decreased synthesis of coagulation factors; a decrease in the concentration factors at the expense of spending as a result of consumption coagulopathy; abnormal synthesis of clotting factors; quantitative and qualitative changes of platelets; reduction in the number of antiplasmin.
In recent years, endovascular surgery serves as an alternative to resection for the treatment of hemangiomas of the liver.
There is a method of rapid assessment of the functional state of the hemostatic system. The essence of the method lies in the fact that they measure electraprobe the ability of the blood by passing through it an alternating current with a frequency of 200 Hz, write electrocoagulator and determined by her timing and amplitude characteristics And the amplitude reduction of the functional curve, mV; T - time reduction of the amplitude functional curve to the minimum value in minutes. With a decrease or increase the value of the indicator A/T relative norms judge violations in the hemostatic system: when values of A/T, equal 3-5, assess the condition of hemostasis as the norm, when values of A/T less than 3 determine the hypocoagulation, and when values of A/T over 5 - hypercoagulation. (Patent RF №2413954).
The known correction method indicators of hemostasis through the use of ozonated physiological solution in which to obtain hypocoagulation effect use of ozone-oxygen gas mixture containing 800-2000 mg/l ozone. It is passed through a container with 200 ml of 0.9%sodium chloride solution for 10 min at a gas flow rate of 0.5-1 l/min is Administered intravenously, at a rate of 5-10 treatments. To accelerate the blood coagulation for local hemostasis using saline, treated with ozone-oxygen gas mixture with ozone 3500-5000 µg/L. Way, you can affect the performance of the hemostatic system. This increases the efficiency and safety of correction of the hemostatic system (Patent RF №2166949). The disadvantage is about the absence of any data on the system of hemostasis in patients with hemangiomas of the liver and its effective correction in pre - and postoperative period.
There is a method of correction of disorders of hemostasis with extensive operations on the organs typical for hepatic-pancreaticoduodenal area, including subcutaneous administration of fraxiparina dose of 0.3-0.6 ml, while the correction of disorders of hemostasis performed intraoperatively, and Fraxiparine enter through the 40-80 min from the start of operations in conjunction with intravenous drip of Mexidol, which is injected at a dose of 5-6 mg/kg of patient's weight, dissolved in 400 ml of 0.9%NaCl solution at 60 drops per minute (RF Patent No. 2279853).
The disadvantages of this method are the contraindications of Mexidol in the liver and kidneys. For hemangiomas of the liver develops reduced levels of prothrombin complex, platelet deficiency of inhibitors of coagulation and impaired fibrinolysis system, the proposed method has a very low degree of efficiency of correction of disorders of hemostasis, as it has, in fact, only antithrombotic effect in combination with the improvement of rheological properties of blood.
This method is chosen as a prototype.
The objective of the invention is to develop an efficient method for the correction of the hemostatic system in patients with hemangiomas of the liver.
The technical result is to increase the efficiency and safety way to adjust the parameters of the system of hemostasis.
The entity from whom retene is that 3 days before endovascular embolization of liver hemangiomas conduct preoperative correction of hemostasis, which prescribe the drug Protonix 600 at a dose of 20 IU/kg, administered intravenously at a rate not exceeding 2 ml/min on the first day after the operation again prescribed the drug Protonix 600 at a dose of 20 IU/kg, optionally, from the first day of the postoperative period, appoint subcutaneous administration of the drug Fraxiparine, dosage 158 IU/kg body weight for 3 days.
These assignments due to the fact that in the study in the preoperative period of hemostasis in children with hemangiomas of the liver were revealed in all its parts. Was identified chronometric hypocoagulation, due to decreased activity factors of the prothrombin complex. With changes both internal and external mechanism was not accompanied by a violation of the final stage of blood coagulation. In the study of platelet-vascular hemostasis was noted desegregation thrombocytopathies with endotheliosis and oppression inner path of fibrinolysis. All this contributed to the increasing trend to increased thrombosis. After endovascular embolization (occlusion) of hemangiomas of the liver revealed a deficiency of factors of internal and external mechanisms swerty the project for blood, namely-vitaminsvitamin factors (II, VII, IX, X, XII). In the study of platelet-vascular hemostasis was noted increased platelet activity and ADP-aggregation oppression inner path of fibrinolysis high endothelium and lower production of anti-thrombin III. These violations contribute to the emergence of processes macrothrombocytopenia. Thus, for a more predictable course of the disease, as well as favorable postoperative period was timely and appropriate correction of disorders of hemostasis, which was the purpose of the drug Protonix 600 for 3 days prior to endovascular embolization of liver hemangiomas, repeated use of the drug was carried out after endovascular embolization for 1 day postoperative period. In parallel with the first day of the postoperative period, was conducted therapy drug Fraxiparine in 3 days.
Protronix 600 is a complex of blood coagulation factors, which is based on replacing the missing factors (II, VII, IX and X), providing hemostatic and regenerating effect in patients with deficiency of these factors.
The method is as follows.
To increase prothrombin complex, preoperative correction of hemostasis start 3 days before PCI is embolizarii hemangioma of the liver. Preparation of a solution of the drug Protonix 600 carried out according to these instructions. The drug is injected slowly at a rate not exceeding 2 ml/min, at a dose of 20 IU/kg Repeated administration of the drug is carried out after endovascular embolization of liver hemangiomas at 1 day post-operative period in the same dosage.
In parallel, starting from 1 day post-operative period for 3 days, exercise therapy drug Fraxiparine by subcutaneous injection at a dosage 158 IU/kg of body weight. Correction of hemostatic disorders carried out under the control of hemostasis.
Clinical example of the method.
Boy P., 1 year 3 months. Diagnosis: multiple hemangioma of the right lobe of the liver. From the anamnesis it is known that during routine ultrasound of the abdomen revealed multiple lesions of the right lobe of the liver (cavernous hemangioma?) sizes from 10×15 mm to 30×50 mm In the preoperative period was carried out a number of instrumental diagnostic studies, including the study of hemostasis (all values are given relative to the normal indicators of hemostasis): in the coagulation hemostasis revealed reduction of the maximum clotting activity in autocompletion test (MA ACT) by 11%. Was lengthening of activated time the river is ecificatio (ABP) in 6.1 seconds, activated partial thromboplastin time (APTT) of 2.2 seconds. Thrombin and prothrombin time was increased by 1.8 seconds. Moderately decreased the number of fibrinogen to 2.7±0.16 g/l In the study with a snake venom ancistrodon test was extended by 3.4 seconds, compared with the control group and 30.7±0,21". In the study of platelet-vascular hemostasis platelet count compared with the control group was reduced to 231,2±10,15±109. The aggregation function of platelets with ADP increased by 3.0 seconds. In addition, the marked increase in the index of platelet activity to 26.5±0.2% and von Willebrand factor by 17.5%. In the study of fibrinolytic system showed increased XII-dependent fibrinolysis 2.3 minutes. When determining the primary physiological anticoagulants revealed a moderate decrease in activity of AT III to 97.4±1.3 percent. Defining markers of intravascular coagulation revealed an increase of orthophenanthroline test 2.3 times, while negative ethanol test.
To increase prothrombin complex, preoperative correction of hemostasis was performed with drug Protonix 600 for 3 days prior to endovascular embolization. The contents of the vial immediately before use was dissolved in 20 ml of sterile 0.9% sodium chloride solution. Obtained the solution should be transparent and should not contain suspended particles. If the drug does not require the definition of a group and rhesus toiletries recipient. The introduction of the drug was carried out intravenously, slowly at a rate not exceeding 2 ml/min, at a dose of 20 IU/kg After 3 days the patient was performed endovascular superselective embolization of hemangiomas of the right lobe of the liver PVA spheres and spirals of Gianturco. The patient's condition corresponded to the severity and volume of made of x-ray treatment. Complications were noted. At 1 day post-operative period was repeated introduction of the drug Protonix 600 as described above. On the same day was initiated concurrent therapy drug Fraxiparine. The drug in the dosage 158 IU/kg body weight was injected into the patient lying, subcutaneously, anterolateral or posterolateral surface of the abdomen. The needle was introduced perpendicularly into the pinched fold of skin formed between thumb and forefinger. The fold of skin supported during the entire period of drug administration. The drug Fraxiparine was injected as described above within 3 days of the postoperative period. At the end of therapy Fraxiparina follow-up study of indicators of hemostasis.
In the study of indicators of hemostasis on the 3rd day of polioviral the frame period revealed the following changes: a study of coagulation hemostasis showed a slight decrease of the maximum clotting activity in autocompletion test (MA ACT) by 1.5%. Was lengthening of activated time rekaltsifikatsii (ABP) 1.4 seconds, activated partial thromboplastin time (APTT) in 2.7 seconds. Revealed a slight increase in thrombin time by 0.6 seconds with normal prothrombin time in 16,1±0.4 sec. Moderately decreased the number of fibrinogen to 2.8±0,13 g/l In the study with a snake venom ancistrodon test is lengthened by 1 second compared with the control group and amounted to 28.3±0,52". In the study of platelet-vascular hemostasis platelet count compared with the control group were not significantly changed (271,2±10×109), does not change the index of platelet activity (24,4±0,4%). The aggregation function of platelets with ADP accelerated slightly (21,5±0,3"). However, there is an increase of von Willebrand factor of 13.8%. The study of the fibrinolytic system have revealed increasing XII-dependent fibrinolysis 2.4 minutes. When determining the primary physiological anticoagulants revealed a moderate decrease in activity of AT III to 97.4±1.3 percent. Defining markers of intravascular coagulation revealed increase of orthophenanthroline test at 1.1 times when negative ethanol test. In a satisfactory condition the child was discharged.
Thus, changes in the indicators in the hemostatic system 3 and the ducks postoperative period, after we conducted specific therapy, showed a positive dynamics of all indicators of hemostasis in comparison with the normal values. There had been a slight hypocoagulation while maintaining normal values of total activity of physiological anticoagulants with minor changes in the vascular and platelet-hemostasis.
The method allows to increase the efficiency and safety of correction of hemostasis disorders in children with hemangiomas of the liver.
The correction method of hemostasis disorders in children with hemangiomas of the liver, including subcutaneous administration of the drug antithrombotic activity, such as Fraxiparine, characterized in that 3 days before endovascular embolization of liver hemangiomas intravenously at a rate not exceeding 2 ml/min injected the drug plasma factors (II, VII, IX, X), blood clotting, such as Protronix 600 at a dose of 20 IU/kg on the first day after surgery, re-enter Protronix the same dosage, and advanced subcutaneously injected Fraxiparine in dosage 158 IU/kg body weight for 3 days.
SUBSTANCE: present invention refers to immunology, namely to an immunostimulating drug containing nano-diamond powder and additionally gold-modified nano-diamonds in the following proportions, wt %: nano-diamond powder - 55; gold-modified nano-diamond powder - 45.
EFFECT: invention provides higher immunobiological activity with low toxicity of the drug.
1 dwg, 1 tbl, 1 ex
SUBSTANCE: invention relates to medicine, namely to phthisiology and can be used with the purpose to increase efficiency of treatment of patients with destructive forms of pulmonary tuberculosis. For this purpose after relief of intoxication manifestations and absence of side effects thymaline in dose 40 mg is introduced to patient in paravasal way 5 days running. After that, 6 days after finishing its introduction, 3% solution of drug glutoxime is introduced in dose 2.0 ml for 10 days. Then, introduced is cycloferon in dose 0.25 g, two times per week until intensive stage of main course is over.
EFFECT: invention makes it possible to reduce terms of elimination of destructive changes in lungs and achieve cessation of mycobacteria release in patients with expressed secondary immunodeficiency.
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of pharmacy and represents gel composition for treatment of nosebleed, containing (a) carboxypolymethylene polymer; (b) glycine; (c) source of calcium ions; and (d) water, where concentration of carboxypolymethylene polymer constitutes from 30 to 40 g of dry substance for 1 litre of gel, concentration of glycine constitutes from 110 to 120 g of dry substance per 1 litre of gel, concentration of calcium ions constitutes from 40 to 70 mg per 1 litre of gel.
EFFECT: invention ensures creation of gel composition, efficient for nosebleed treatment.
12 cl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: stable fat emulsion contains prostaglandin as an active ingredient and phospholipids containing phosphatidylcholine and phosphatidyl glycerol in mass ratio 85:15 to 99.7:0.3. The fat emulsion under the invention and its active ingredient (prostaglandin) possess physical and chemical stability thereby increasing shelf life to approximately two years, and/or extended range of storage temperature to 10°C as compared with a commercially available fat prostaglandin emulsion.
EFFECT: fat emulsion under the invention enables satisfactory effectiveness even in the introduction of a low amount.
25 cl, 10 tbl, 12 ex
SUBSTANCE: invention refers to biotechnology, namely plasmid DNA pCID-PROC for expression of recombinant human protein C, cell lines of Chinese hamster ovary DG-CID-PROC-1 and a method for producing recombinant human protein C. The presented invention may be used for producing recombinant human protein C. Plasmid DNA pCID-PROC for expression of recombinant human protein C contains a sequence of full-length complementary DNA of a human protein C gene presented in List of Sequences as the sequence SEQ ID NO: 1. Plasmid DNA pCID-PROC is characterised by a physical map presented on dwg. 1. A cell line of Chinese hamster ovary DG-CID-PROC-1 is produced by transformation of the cell line of Chinese hamster ovary DG-44 by said expression plasmid DNA pCID-PROC. The method for producing recombinant human protein C involves culture of said cell line DG-CID-PROC-1 in a nutrient medium and recovery of produced target protein from a culture fluid.
EFFECT: invention provides higher production performance of the protein C expression system and simplified recovery, activation and purification of recombinant activated human protein C.
3 cl, 3 dwg, 2 ex
SUBSTANCE: invention relates to biotechnology and specifically to obtaining factor VII (FVII) and factor Vila (FVIIa) albumin linked polypeptides, and can be used in medicine. A polypeptide, which is a FVII or FVIIa polypeptide is obtained in a recombinant manner, said peptide being linked with albumins through a glycerine-serine peptide linker of a special structure, which separates part associated with FVII or FVIIa from the albumin part, wherein the FVII or FVIIa polypeptide lies on the N-end of the fused protein. The linked polypeptide or vector structure, which contains its coding nucleic acid, is used as a medicinal agent for treating or preventing blood-clotting disorders.
EFFECT: invention enables to obtain a protein with FVII or FVIIa biological activity and longer functional half-time in plasma in vitro compared to non-linked FVII or FVIIa.
12 cl, 4 dwg, 6 tbl, 6 ex
SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for sealing interintestinal anastomosis. For this purpose before immersion into abdominal cavity and suturing middle wound, application of 30-40 g of dry lyophilised cryoprecipitate is performed on serous cover of small intestine on entire circumference of interintestinal anastomosis. After that, either 2-3 ml of 5% calcium chloride solution or 4-5 ml of sterile thrombin 15 U NIH/ml, dissolved in 5% solution of aminocaproic acid, are added drop by drop into said cryoprecipitate. 60 seconds after formation of gel-like fibrin film re-application of the first or the second two-component composition is carried out.
EFFECT: method ensures increase of strength and biological impermeability of intestinal sutures at the background of extensive peritonitis due to efficient fixation of fibrin, which does not produce damaging impact on tissues, is capable of quick formation of fibrin film, is homologous and safe, penetrates zone of suture, filling holes from needle punctures, making it possible to close anastomosis on circumference evenly.
4 dwg, 4 ex
SUBSTANCE: group of inventions refers to medicine, namely traumatology and surgery, and may be used for bleeding control. That is ensured by the use of a composition, as well as an adhesive material containing gelatin and transglutaminase wherein their relation is sufficient for bleeding control in a wound, and wherein said gelatin is not exposed to irreversible gel-formation and forms a solution with transglutaminase at temperature below natural one of a gel-sol junction of standard animal gelatin prepared from an animal source or representing recombinant gelatin or their combination.
EFFECT: use of the given inventions enables reducing time of bleeding control in the wound.
22 cl, 15 dwg, 12 tbl, 15 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: in formula (1): R1 means haloalkyl containing 1-6 fluorine atoms; R2 means C1-C6alkyl or halogen; R3 means -L-NR4R5, -X-NR-C(O)R8 or -X-NR-C(O)NR4R5 wherein L means -X-C(O), -(CR2)j, -O(CR2)1-4 or and X means (CR2)j or [C(R)(CR2OR)]; R4 and R5 independently mean H, C1-C6alkyl, halogen-substituted C1-C6alkyl, hydroxy group-substituted C1-C6alkyl, or (CR2)k-R6; R8 independently means (CR2)k-R6 or C1-C6alkyl, or halogen-substituted C1-C6alkyl; R7 means H; alternatively, R4 and R5 together with N atom in each NR4 R5 form a 4-7-member heterocyclic ring containing 1 -2 heteroatoms independently specified in N and O substituted by 0-3 groups R11; R11 means R8, (CR2)k-OR7, CO2R7, (CR2)k-C(O)-(CR2)k-R8, (CR2)kC(O)NR7R7 or (CR2)kS(O)1-2R8; each R means H or C1-C6alkyl; each k is equal to 0-6; and j and m are independently equal to 0-4; provided R1 does not mean trifluoromethoxygroup, provided R3 means C(O)NH2, C(O)NR12R13; wherein R12 and R13 together form piperazinyl; the values of the radical R6 are presented in the patent claim. The invention also refers to the pharmaceutical composition containing said compounds.
EFFECT: producing new 5-(4-(halogenalkoxy)phenyl)pyrimidin-2-amine derivatives showing c-kit, PDGFRα, PDGFRβ kinase inhibitory activity, optionally in the form of isomers or pharmaceutically acceptable salts.
12 cl, 77 ex, 1 tbl
SUBSTANCE: invention refers to medicine, particularly to applying a neutralising antibody to matrix metalloproteinase-10 (MMP-10) for preparing a drug applicable for antifibrinolytic therapy and treating bleedings and hemorrhagic complications of various aetiology: hyperfibrinolytic conditions caused by congenital pathologies, anticoagulant therapy, surgical procedures.
EFFECT: invention provides higher selectivity of inhibitors which block molecular mechanisms associated with specific matrix metalloproteinases that allows avoiding undesired events.
7 cl, 4 ex, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to new compounds of general formula I [X]n-Y-ZR1R2, wherein the radicals are specified in the description, effective as heparan sulphate-binding protein inhibitors. The invention also refers to a pharmaceutical or veterinary composition having heparan sulphate-binding protein inhibitory activity for preventing or treating a disorder in a mammal, and to the use of these compounds and compositions for antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic therapy in a mammal.
EFFECT: preparing the new compounds of general formula I [X]n-Y-ZR1R2, wherein the radicals are specified in the description, effective as the heparan sulphate binding protein inhibitors.
10 cl, 31 ex, 11 tbl, 40 dwg
SUBSTANCE: invention relates to compounds of formula 1 , where X and T are N or C, Q is a (3-7)-member aromatic ring which contains 0-3 nitrogen atoms as ring members, and which is optionally benzo-condensed and is substituted with oxo; C1-C6-alkyl; halogen- C1-C6-alkyl; hydroxy-C1-C6-alkyl; C1-C6-alkoxy; C6-C10-aryl; or a (3-7)-member heteroaryl containing 1-3 oxygen atoms, P is C1-C6-alkyl, optionally substituted with a halogen, and R is a group selected from: (i) -C1-C6-alkyl-R1, (ii) -NR2R3, (iii) -O-R4, (iv) -S-R5, (v) -C (=O))-R6, (vi) optionally substituted (3-7)-member heteroaryl containing 1-4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulphur atom, (vi) optionally substituted (3-7)-member heteroatom containing 1-4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulphur atom, (vii) optionally substituted, saturated or partially unsaturated, separate or condensed (3-10)-member heterocyclic ring containing 1-4 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulphur atom, (viii) azido; where each R1, R2, R3, R4, R3, R6, is as described in the claim. The invention also relates to a pharmaceutical composition for preventing and treating a vascular disease, which contains a compound of formula 1.
EFFECT: compounds of formula 1 with inhibitory activity with reference to aggregation of thrombocytes.
7 cl, 7 dwg, 2 tbl, 519 ex
SUBSTANCE: invention refers to medicine, namely coagulology, and may be used in treating acute venous thrombosis of various localisations in the clinical conditions accompanied by existing or else threatening hemorrhagic complications. For this purpose, with underlying intake of low-molecular heparins (LMHs) in preventive doses, human Antithrombin III 1000 IU is additionally introduced every three days; total course dose is 5000-10000 IU.
EFFECT: method provides higher clinical effectiveness ensured by intensified antithrombotic potential of LMH with causing no hemorrhagic syndrome aggravations in the patients having both low, and normal endogenic antithrombin III level.
1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention provides compositions containing clopidogrel and sulphoalkylester cyclodextrin (SAE-CD), preferentially, sulphobutylester cyclodextrin. The compositions may be liquid, suspension and solid. The compositions are prepared for ingestion, oral or enteral introduction. SAE-CD is used as an agent promoting clopidogrel dissolution and stabilisation in an aqueous media. Higher stability of clopidogrel to hydrolytic, thermal and photolytic degradation is provided. SAE-CD gives better effect as compared with the other cyclodextrin derivatives. The compositions under the invention reduce chiral inversion rate (S) of clopidogrel into (R)-clopidogrel.
EFFECT: compositions give substantial pharmacokinetic, pharmacodynamics and/or therapeutic advantages as compared with a tablet composition introduced orally and not containing SAE-CD.
58 cl, 18 dwg, 14 tbl, 27 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to chemical-pharmaceutical industry, medicine, pharmacology and represents medication for prevention and treatment of atherosclerotic lesion of blood vessels, as well as pre- and thrombotic states, which possesses hypolipidemic and anticoagulant and antithrombotic activity, and is made in dosed drug form in form of coated tablets, consisting of core, which contains active substance and auxiliary substances, characterised by the fact that core contains substance of sulfated arabinogalactan potassium salt as active ingredient, and ludipress, aerosol and sodium stearate as auxiliary substances, components in medication being in definite ratio in wt %.
EFFECT: invention ensures efficient treatment and prevention of atherosclerotic lesion of blood vessels, as well as pre- and thrombotic states.
4 cl, 5 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to formula 1 compounds, possessing properties of Xa factor inhibitors, their pharmaceutically acceptable salts and based on them pharmaceutical compositions. In formula 1 cycle A stands for residue, selected from group, including the following structures: R1-R12 independently represents H, (C1-C7)alkyl or (C3-C7)cycloalkyl, R3 and R4 form cycle by binding (C3-C5)alkylene, alkylene carbon atom can be substituted with carbonyl; R13 stands for H, (C1-C7)alkyl or formyl.
EFFECT: obtaining compounds, possessing properties of Xa factor inhibitors.
8 cl, 5 ex, 3 tbl, 22 ex
SUBSTANCE: invention relates to field of medicine and can be applied in cardiosurgery, namely in treatment of patients with tricuspid valve pathology. Method of patient management after tricuspid valve prosthetics includes constant continuous life-long application of warfarin and aspirin, periodic application by indications of heparin, fraxiparin, freshly frozen plasma and vitamin K1, correction of warfarin dose being carried out depending on value of international normalised ratio (INR) in venous blood plasma.
EFFECT: method is aimed at prevention of thrombus-formation and hemorrhagic complications in all types of tricuspid valve prosthetics with both mechanical and biological prosthetes and makes it possible to achieve reduction of number of thrombotic and hemorrhagic complications in patients with prosthetic tricuspid valve and improvement of surgery results.
8 cl, 1 tbl
SUBSTANCE: invention refers to medicine, and may be used for introducing an anticoagulative system in a subject wherein the system involves an aptamer which binds factor IX/IXa, and an antidote which binds the aptamer. That is ensured by measuring subject weight in kilograms. A dose of the aptamer effective to inhibit coagulation in the subject is introduced wherein the aptamer contains the sequence SEQ ID No:1, and wherein the dose of the aptamer makes approximately 0.1 mg/kg to approximately 2.0 mg/kg, or approximately 5 mg/kg to 10 mg/kg. It is followed by introducing a dose of the aptamer antidote in the subject wherein the antidote contains the sequence SEQ ID No:2, and the dose of the antidote is exclusively based on the relation of weight/weight with the dose of the aptamer, and wherein the relation of weight/weight of the dose of the antidote with the dose of the aptamer makes approximately 0.1:1 to approximately 20:1.
EFFECT: invention provides a lower risk of developing haemorrhage in the subject, an immediate therapeutic effect, easy dosage, predictable reversibility of anticoagulative system action.
24 dwg, 7 tbl
SUBSTANCE: present invention relates to substances of the heterylammonium 4-aryl-2-hydroy-4-oxo-2-butenoates class, and specifically to thiazoline ammonium 2-hydroxy-4-oxo-4-(4-chlorophenyl)-2-butenoate, having anticoagulation activity, of formula: .
EFFECT: obtaining a substance with anticoagulation activity.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutical industry, namely a combination of clopidogrel and ethylmethylhydroxypyridine. A composition on the basis of the combination is presented in the form of a solid pharmaceutical composition, namely in the form of capsules.
EFFECT: composition of clopidogrel and ethylmethylhydroxypyridine is promising for prevention and treatment of obesity, pathological cardiovascular conditions prevention of ischemic disorders with manifested atherosclerosis, suffered infarction, ischemic stroke, peripheral arterial disease.
2 cl, 2 tbl
SUBSTANCE: invention refers to medicine and is intended to prevent the age-related changes of hepatic tissue in rats experimentally. What is used is the biologically active additive "Rekicen RD" added to the diet of inbred laboratory rats at the age of two years old. A dose is 2 grams a day for 14 days.
EFFECT: method enables improving the hepatic tissue state ensured by increasing the regeneration activity of hepatocytes.